Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer

Journal of Clinical Oncology

Volumn 27, Issue 4, 2009, Pages 526-534

  Baselga, José ^a   Zambetti, Milvia ^b   Llombart Cussac, Antoni ^b   Manikhas, Georgy ^b   Kubista, Ernst ^b   Steger, Günther G ^b   Makhson, Anatoly ^b   Tjulandin, Sergei ^b   Ludwig, Heinz ^b   Verrill, Mark ^b   Ciruelos, Eva ^b   Egyhazi, Suzanne ^b   Xu, Li An ^b   Zerba, Kim E ^b   Lee, Hyerim ^b   Clark, Edwin ^b   Galbraith, Susan ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ESTROGEN RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IXABEPILONE; MESSENGER RNA; TAU PROTEIN;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BONE PAIN; BREAST ADENOCARCINOMA; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE EXPRESSION PROFILING; HUMAN; INVASIVE CARCINOMA; LEUKOPENIA; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; STOMATITIS; VOMITING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RNA, MESSENGER;

EID: 59149087388     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.2646     Document Type: Article

References (42)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival. Lancet 365:1687-1717, 2005
2. Conlin AK, Seidman AD: Taxanes in breast cancer: An update. Curr Oncol Rep 9:22-30, 2007
3. Wardley A: Capecitabine: Expanding options for the treatment of patients with early or locally advanced breast cancer. Oncologist 11:20-26, 2006 (suppl)
4. Ayers M, Symmans WF, Stec J, et al: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22:2284-2293, 2004
5. Gianni L, Zambetti M, Clark K, et al: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265-7277, 2005
6. Hess KR, Anderson K, Symmans WF, et al: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-4244, 2006
7. Wolmark N, Wang J, Mamounas E, et al: Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96-102, 2001
8. Bear HD, Anderson S, Smith RE, et al: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027, 2006
9. Lee FY, Borzilleri R, Fairchild CR, et al: BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429-1437, 2001
10. Wartmann M, Altmann KH: The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2:123-148, 2002
11. Bollag DM, McQueney PA, Zhu J, et al: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333, 1995
12. Low JA, Wedam SB, Lee JJ, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23:2726-2734, 2005
13. Roché H, Yelle L, Cognetti F, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 25:3415-3420, 2007
14. Thomas E, Tabernero J, Fornier M, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25:3399-3406, 2007
15. Perez EA, Lerzo G, Pivot X, et al: Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407-3414, 2007
16. Fojo AT, Menefee ME, Poruchynsky M, et al: A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): Assessment of its activity and demonstration of target engagement in tumor cells. J Clin Oncol 23:16S, 2005 (suppl; abstr 4541)
17. Galsky MD, Small EJ, Oh WK, et al: Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23:1439-1446, 2005
18. Hussain M, Tangen CM, Lara PN Jr, et al: Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A Southwest Oncology Group trial S0111. J Clin Oncol 23:8724-8729, 2005
19. O'Connor O, Straus D, Moskowitz C, et al: Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone analog BMS 247550 induces major and durable remissions in very drug resistant disease. J Clin Oncol 23:16S, 2005 (suppl; abstr 6569)
20. Smith SM, Pro B, van Besien K, et al: A phase II study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin's lymphomas. J Clin Oncol 23:16S, 2005 (suppl; abstr 6625)
21. Whitehead RP, McCoy S, Rivkin SE, et al: A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study. Invest New Drugs 24:515-520, 2006
22. Thomas E, Gomez HL, Li RK, et al: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217, 2007
23. Sataloff DM, Mason BA, Prestipino AJ, et al: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 180:297-306, 1995
24. McCarty KS Jr, Miller LS, Cox EB, et al: Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109:716-721, 1985
25. Staunton JE, Slonim DK, Coller HA, et al: Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98:10787-10792, 2001
26. Irizarry RA, Hobbs B, Collin F, et al: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249-264, 2003
27. Guyon I, Weston J, Barhill S, et al: Gene selection for cancer classification using support vector machines. Machine Learning 46:389-422, 2002
28. Wilson E: Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 22:209-212, 1927
29. Clopper C, Pearson E: The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404-413, 1934
30. Rouzier R. Radhika R, Wagner P, et al: Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102:8315-8320, 2005
31. Hayes DF, Thor AD, Dressler LG, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506, 2007
32. Gradishar WJ, Wedam SB, Jahanzeb M, et al: Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol 16:1297-1304, 2005
33. Buzdar AU, Singletary SE, Theriault RL, et al: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17:3412-3417, 1999
34. Demaria S, Volm MD, Shapiro RL, et al: Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 7:3025-3030, 2001
35. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174, 2003
36. Green MC, Buzdar AU, Smith T, et al: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983-5992, 2005
37. Gianni L, Baselga J, Eiermann W, et al: Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 11:8715-8721, 2005
38. Amat S, Bougnoux P, Penault-Llorca F, et al: Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 88:1339-1345, 2003
39. Roche H, Perez E, Llombart-Cussac A, et al: Ixabepilone, an epothilone B analog, is effective in ER, PR, HER-2 negative (triple negative) patients: Data from neoadjuvant and metastatic breast cancer trials. Ann Oncol 17:S93-S113, 2006, (suppl 9)
40. Baselga J, Gianni L, Llombart A, et al: Predicting response to ixabepilone: Genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer. Breast Cancer Res Treat 94:S31-S32, 2005 (suppl; abstr 305)
41. Llombart A, Baselga J, Manikhas G, et al: Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): Preliminary efficacy and safety data. J Clin Oncol 23:16S, 2005 (suppl; abstr 586)
42. Lee H, Xu L, Wu S, et al: Predictive biomarker discovery and validation for the targeted chemotherapeutic ixabepilone. J Clin Oncol 24:18S, 2006 (suppl; abstr 3011)